- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05497596
The Association Between Human Microbiome and Vitamin D in Chronic Urticaria
Study Overview
Detailed Description
Urticaria is a chronic allergic inflammatory disorder. Genetic and environmental factors, such as exposure to allergens and microbes, have a detrimental role in the development of chronic urticaria. Vitamin D also has an important role in urticaria. Lower sera vitamin D level was observed in patients that developed urticaria. Vitamin D binding protein (DBP) bound to vitamin D and regulated its metabolites in the circulation. Moreover, vitamin D receptors (VDR) have been identified on nearly all cells of the immune system. It may contribute to maintenance of intestinal barrier function by preventing increased intestinal permeability, dysbiosis, inflammation, and a lack of immune tolerance in the gut.
The investigators plan to design a double-blind trial to evaluate the role of human microbiome and vitamin D in the development of urticaria. We will enroll children with chronic urticaria (CU) and age and gender matched healthy children,and collected their venous blood and microbiome samples of nasal and anal swab. Then, CU subjects will be given vitamin D or placebo for 6 months in a randomized, double-blind way. After six months of follow-up, their blood, nasal cavity, and intestinal bacterial samples were taken. All microbial analysis, allergen detection, vitamin D concentration, VDR, DBP genotype will be analyzed by the core laboratory and bioinformatics center of CMUH.
The investigators believe this study can answer the cause-effect relationships of microbiota and vitamin D in the development of CU, and design a microbiota-related preventive and treatment strategy.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jiu-Yao Wang, MD
- Phone Number: 4131 886422052121
- Email: aim.cmuh@gmail.com
Study Locations
-
-
-
Taichung, Taiwan, 404
- Recruiting
- China Medical University Hospital
-
Contact:
- Jiu-Yao Wang, MD
- Phone Number: 4131 886422052121
- Email: aim.cmuh@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Experimental group: patients with chronic spontaneous urticaria under the age of 18 .
- Control group: healthy children under the age of 18 (eg, healthy siblings of sick children).
Exclusion Criteria:
- Recruit patients who have used antibiotics, systemic steroids, and immunosuppressants in the previous month.
- Patients with C1 esterase inhibitor deficiency, lymphocytopenia, thrombocytopenia, severe diseases involving heart, liver, or kidney, metabolic disease, or autoimmune disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Control group
placebo
|
Placebo
|
|
Experimental: Treatment group
Vitamin D (2000IU/day) for 6 months
|
Vitamin D (2000IU/day) for 6 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Levels of vitamin D
Time Frame: Month 0
|
Vitamin D will be measured in a blood sample by ELISA to determine baseline status.
|
Month 0
|
|
Levels of vitamin D
Time Frame: Month 6
|
Vitamin D will be measured in a blood sample to follow the change from baseline in vitamin D level at month 6.
|
Month 6
|
|
Single nucleotide polymorphism of vitamin D receptor and vitamin D binding protein.
Time Frame: Month 0
|
Single nucleotide polymorphism (SNP) genotyping will be performed in a blood sample by using TaqMan SNP genotyping assays.
|
Month 0
|
|
Microbiome Microbiome
Time Frame: Month 0
|
Nasal and anal swabs will be used to detect respiratory and intestinal microbiome by using 16S rRNA sequencing to determine baseline status.
|
Month 0
|
|
Microbiome Microbiome
Time Frame: Month 6
|
Nasal and anal swabs will be used to detect respiratory and intestinal microbiome by using 16S rRNA sequencing,and to follow the change from baseline in microbiome at month 6.
|
Month 6
|
|
Total IgE
Time Frame: Month 0
|
Plasma total IgE concentration will be measured by microparticle immunoassay (IMx analyzer, Abbott Laboratories, Abbott Park, IL) and ELISA to determine baseline status.
|
Month 0
|
|
Total IgE
Time Frame: Month 6
|
Plasma total IgE concentration will be measured by microparticle immunoassay (IMx analyzer, Abbott Laboratories, Abbott Park, IL) and ELISA to follow the change from baseline in total IgE at month 6.
|
Month 6
|
|
Allergen-specific IgE
Time Frame: Month 0
|
Plasma allergen-specific IgE will be measured by BioIC ®.
|
Month 0
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Life Assessment
Time Frame: Month 0 to Month 6
|
Patients will rate their CU symptoms and the impact of their CU on various aspects of their lives.
Each question is scored from 0 (not at all) to 3 (very much).
Overall score, on scale of 0 to 57.
|
Month 0 to Month 6
|
|
The Urticaria Activity Score 7 (UAS7)
Time Frame: Month 0 to Month 6
|
The Urticaria Activity Score 7 measures number the weekly average of hives and pruritus measured twice a day.
It scores from 0 to 42.
|
Month 0 to Month 6
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CMUH111-REC3-066
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.